Effect of recombinant human growth hormone on serum Klotho and fibroblast growth factor 23 in children with idiopathic short stature.
10.7499/j.issn.1008-8830.2306105
- Author:
Han-Han DONG
1
;
Meng-Meng LI
1
;
Meng SUN
1
;
Ran ZHOU
1
;
Xin-Ying ZHANG
1
;
Ya-Ying CHENG
1
Author Information
1. Department of Pediatrics, Hebei Provincial People's Hospital, Shijiazhuang 050051, China.
- Publication Type:Journal Article
- Keywords:
Child;
Fibroblast growth factor 23;
Idiopathic short stature;
Insulin-like growth factor-1;
Klotho;
Physical development
- MeSH:
Child;
Humans;
Human Growth Hormone/pharmacology*;
Insulin-Like Growth Factor I/pharmacology*;
Fibroblast Growth Factor-23;
Prospective Studies;
Growth Disorders;
Phosphates/pharmacology*;
Body Height
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(11):1143-1149
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the changes in the serum levels of Klotho, fibroblast growth factor 23 (FGF23), and insulin-like growth factor-1 (IGF-1) in children with idiopathic short stature (ISS) before and after recombinant human growth hormone (rhGH) treatment, as well as the correlation of Klotho and FGF23 with the growth hormone (GH)/IGF-1 growth axis in these children.
METHODS:A prospective study was conducted on 33 children who were diagnosed with ISS in the Department of Pediatrics, Hebei Provincial People's Hospital, from March 10, 2021 to December 1, 2022 (ISS group). Twenty-nine healthy children, matched for age and sex, who attended the Department of Child Healthcare during the same period, were enrolled as the healthy control group. The children in the ISS group were treated with rhGH, and the serum levels of Klotho, FGF23, and IGF-1 were measured before treatment and after 3, 6, and 9 months of treatment. A correlation analysis was conducted on these indexes.
RESULTS:There were no significant differences in the serum levels of IGF-1, Klotho, and FGF23 between the ISS and healthy control groups (P>0.05). The serum levels of Klotho, FGF23, and IGF-1 increased significantly in the ISS group after 3, 6, and 9 months of rhGH treatment (P<0.05). In the ISS group, Klotho and FGF23 levels were positively correlated with the phosphate level before treatment (P<0.05). Before treatment and after 3, 6, and 9 months of rhGH treatment, the Klotho level was positively correlated with the IGF-1 level (P<0.05), the FGF23 level was positively correlated with the IGF-1 level (P<0.05), and the Klotho level was positively correlated with the FGF23 level (P<0.05), while Klotho and FGF23 levels were not correlated with the height standard deviation of point (P>0.05).
CONCLUSIONS:The rhGH treatment can upregulate the levels of Klotho, FGF23, and IGF-1 and realize the catch-up growth in children with ISS. Klotho and FGF23 may not directly promote the linear growth of children with ISS, but may have indirect effects through the pathways such as IGF-1 and phosphate metabolism. The consistent changes in Klotho, FGF23 and IGF-1 levels show that there is a synergistic relationship among them in regulating the linear growth of ISS children.
